College of Life Sciences and Medicine, Zhejiang Sci-Tech University, 310018 Hangzhou, People's Republic of China.
Laboratory of Computational Biology, Biological Solution Centre (BioSol Centre), Jashore 7408, Bangladesh.
Biosci Rep. 2022 Nov 30;42(11). doi: 10.1042/BSR20221108.
Renal cell carcinoma (RCC) is a type of cancer that develops in the renal epithelium of the kidney. It is responsible for approximately 3% of adult malignancies, and 90-95% of neoplasms originate from the kidney. Advances in tumor diagnosis, innovative immune therapeutics, and checkpoint inhibitors-based treatment options improved the survival rate of patients with RCC accompanied by different risk factors. RCC patients with diabetes, hepatitis C virus (HCV), or obesity (OB) may have a comorbidity, and finding the risk factor for better clinical treatment is an urgent issue. Therefore, the study focused on network-based gene expression analysis approaches to learning the impact of RCC on other comorbidities associated with the disease. The study found critical genetic factors and signal transduction pathways that share pathophysiology and commonly use dysregulated genes of the illness. Initially, the study identified 385 up-regulated genes and 338 down-regulated genes involved with RCC. OB, chronic kidney disease (CKD), type 2 diabetes (T2D), and HCV significantly shared 28, 14, 5, and 3 genes, respectively. RCC shared one down-regulated gene versican (VCAN) with OB and HCV and one down-regulated gene oxidase homolog 2 (LOXL2) with OB and CKD. Interestingly, most of the shared pathways were linked with metabolism. The study also identified six prospective biomarkers, signaling pathways, and numerous critical regulatory and associated drug candidates for the disease. We believe that the discovery will help explain these diseases' complicated interplay and aid in developing novel therapeutic targets and drug candidates.
肾细胞癌 (RCC) 是一种发生在肾脏肾上皮的癌症。它占成人恶性肿瘤的 3%左右，90-95%的肿瘤来源于肾脏。肿瘤诊断技术的进步、创新的免疫治疗方法和基于检查点抑制剂的治疗选择提高了伴有不同危险因素的 RCC 患者的生存率。患有糖尿病、丙型肝炎病毒 (HCV) 或肥胖症 (OB) 的 RCC 患者可能存在合并症，寻找更好的临床治疗风险因素是当务之急。因此，该研究侧重于基于网络的基因表达分析方法，以了解 RCC 对与疾病相关的其他合并症的影响。该研究发现了关键的遗传因素和信号转导途径，这些因素共享病理生理学，并共同使用疾病失调的基因。研究最初确定了 385 个上调基因和 338 个下调基因与 RCC 相关。OB、慢性肾脏病 (CKD)、2 型糖尿病 (T2D) 和 HCV 分别显著共享 28、14、5 和 3 个基因。RCC 与 OB 和 HCV 共享一个下调基因 versican (VCAN)，与 OB 和 CKD 共享一个下调基因氧化酶同源物 2 (LOXL2)。有趣的是，大多数共享途径与代谢有关。该研究还确定了六个有前景的生物标志物、信号通路以及许多针对该疾病的关键调控和相关药物候选物。我们相信，这一发现将有助于解释这些疾病的复杂相互作用，并有助于开发新的治疗靶点和药物候选物。
